Whitworth J A, Morgan D, Maude G H, Luty A J, Taylor D W
Medical Research Council Laboratory, Bo, Sierra, Leone.
Trans R Soc Trop Med Hyg. 1992 May-Jun;86(3):277-80. doi: 10.1016/0035-9203(92)90308-y.
Clinical and parasitological responses were studied in villagers receiving all 4 doses of treatment, at 6-monthly intervals, in a placebo-controlled community trial of ivermectin for onchocerciasis in Sierra Leone. Skin microfilarial loads were markedly lowered by ivermectin throughout and there were reductions in the severity, but not the prevalence, of skin lesions. Markers of general health and the prevalences of itching, Onchocerca nodules and visual loss were not significantly reduced during the study period. Despite our inability to demonstrate obvious clinical benefit, treatment with ivermectin was well accepted throughout the study. Simple clinical measures for evaluating the short to medium term impact of the mass distribution of ivermectin on populations with onchocerciasis need further development.
在塞拉利昂开展的一项关于伊维菌素治疗盘尾丝虫病的安慰剂对照社区试验中，对每6个月接受4剂治疗的村民的临床和寄生虫学反应进行了研究。伊维菌素使皮肤微丝蚴负荷在整个过程中显著降低，皮肤病变的严重程度有所减轻，但患病率未降低。在研究期间，总体健康指标以及瘙痒、盘尾丝虫结节和视力丧失的患病率没有显著降低。尽管我们无法证明有明显的临床益处，但在整个研究过程中，伊维菌素治疗的接受度良好。评估伊维菌素大规模分发对盘尾丝虫病患者群体的短期至中期影响的简单临床措施需要进一步完善。
